A study of GS-1206 for people with solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called GS-1206 for adults with solid tumors that have a specific genetic change. It aims to see if the drug is safe and can shrink or slow the growth of the cancer after other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that has spread or cannot be removed by surgery, and it has a specific genetic mutation found by a standard test.
- Your cancer must have gotten worse after at least one standard treatment, or you cannot take or refuse standard therapy.
- You cannot have had certain other cancer drugs, like chemotherapy or immunotherapy, within 3 to 4 weeks before starting this study.
- You cannot have had major surgery or radiation within the past 3 to 4 weeks, unless it's a minor procedure or limited radiation for pain.
- You must be willing to follow the study schedule and restrictions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, IMGS-001, in people with advanced solid tumors that have grown back or not responded to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.
This trial tests a new drug called GS-0201, either by itself or with other treatments, for people with advanced solid tumors. The goal is to see if it is safe and helpful.
This trial tests a new drug, GS-2121, given alone or with other therapies, for adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
This trial tests an experimental pill called GenSci122 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.